RecruitingNCT07146100

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate the Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection


Sponsor

Ausper Biopharma Co., Ltd.

Enrollment

200 participants

Start Date

Aug 28, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Capable of giving informed consent.
  • Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.

Exclusion Criteria2

  • Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
  • Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

AusperBio Investigational Site

Guangzhou, Guangdong, China

AusperBio Investigational Site

Changchun, Jilin, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07146100


Related Trials